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Abstract
The Ras superfamily of small GTPases are master regulators of numerous essential processes within 
the cell, so that when they malfunction, cancer and many other diseases can result. For example, 
activating Ras mutations are present in approximately 20% of human cancers. As such, they are key 
therapeutic targets, yet more than three decades of intensive research efforts have failed to 
produce effective Ras inhibitors in the clinic. This is, in part, due to their relatively smooth surfaces 
which are difficult to target through traditional drug discovery methods using small molecules. 
Peptides offer a solution to this issue as they occupy larger surface areas on their targets and 
therefore offer exquisite selectivity and affinity. However, their use in the past has been limited to 
extracellular targets due to delivery issues. Recent advances in peptide macrocyclization, 
modifications and delivery methods have ignited increased interest in the use of these highly 
effective biologics for intracellular targets. This review will cover progress made in the development 
of peptides targeting small GTPases to treat a wide range of diseases.
1 Introduction
There are more than 150 small GTPases in humans comprising the Ras superfamily, which is divided 
into Ras, Rho, Rab, Ran and Arf families based on sequence homology and physiological function 
(Figure 1A). The Ras (Rat sarcoma) family regulates cell proliferation and survival, Rho (Ras 
homologous) family members are master regulators of actin cytoskeletal rearrangement and cell 
motility, Rab (Ras-like in brain) proteins regulate membrane trafficking, Ran (Ras-like nuclear) is 
involved with nucleocytoplasmic transport and Arf (ADP ribosylation factors) proteins regulate 
vesicle trafficking.1
All small GTPases share a conserved G domain of ~20 kDa which binds the guanine nucleotides GDP 
and GTP with high affinity, involving coordination of a magnesium cation. These proteins exist in two 
conformationally distinct states: they are inactive when bound to GDP and active in the GTP-bound 
state where they are competent to bind downstream effectors (Figure 1B). Conformational 
differences between the two states are greatest in the two flexible regions termed switch I (Ras 
numbering 30-38) and switch II (residues 59-67): most effector and regulatory proteins bind to one 
or both of these regions to sense the nucleotide status of the protein. Small GTPases have the 
potential to hydrolyse GTP to GDP rendering them inactive but intrinsic rates of hydrolysis are very 
slow, as is the exchange of GDP for GTP. Signalling is therefore negatively regulated by GTPase 
Activating Proteins (GAPs), which aid hydrolysis of GTP to GDP, while activation is controlled by 
another set of proteins known as Guanine nucleotide Exchange Factors (GEFs), which assist 
replacement of GDP for GTP. The majority of Ras superfamily members are modified by a prenyl 
group, which, often in conjunction with a second membrane-anchoring signal, targets them to 
specific cellular membranes, with this membrane localization being essential for their activity. In 
addition to GEFs and GAPs, the Ras, Rho and Rab proteins are negatively regulated by Guanine 
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nucleotide Dissociation Inhibitors (GDIs) and GDI-like proteins, which promote cytosolic localization 
by binding and masking the prenyl group modifications. 
As these proteins regulate many vital cellular processes, their aberrant signalling can have disastrous 
consequences and they are heavily implicated in a variety of human diseases including cancer,2,3 
vascular diseases4 and immune disorders.5 Although they are highly desirable drug targets, several 
features of small GTPases make them difficult to target through traditional methods of drug 
discovery, leading them to be previously considered ‘undruggable’. In contrast to the success that 
has been attained with ATP-competitive inhibitors for kinases, the picomolar affinity exhibited by 
small GTPases for their nucleotides, along with intracellular GTP concentrations of ~1 mM, makes 
the nucleotide binding site of these proteins an intractable target for competitive inhibitors. 
Inhibition of membrane association to block GTPase signalling has been explored. Early attempts to 
disrupt Ras signalling used farnesyltransferase inhibitors (FTIs) to block prenylation of the Ras C-
terminus and hence the membrane association that is required for transformation.6 Unfortunately, 
FTIs failed in clinical trials and it was later discovered that KRas and NRas proteins, the isoforms most 
commonly mutated in human cancers, can undergo alternative prenylation by 
Geranylgeranyltransferase (GGTase) I in the presence of FTIs.7 Dual inhibition of both these enzymes 
is not expected to be feasible due to their large number of targets, which is likely to lead to toxic 
side effects. Recently however, Novotny et al.  have reported a novel method to mislocalize KRas by 
developing neo-substrates of farnesyltransferase, which modify KRas at the Cys sidechain that is 
normally farnesylated. This modification prevented further processing and membrane attachment, 
resulting in cytoplasmic localization of KRas.8 This approach circumvents issues previously seen with 
FTIs (which are competitive inhibitors of farnesylation) as the modified KRas cannot be prenylated by 
GGTase I, offering a promising new avenue to target Ras signalling. Further, unlike the other Ras 
isoforms, HRas cannot undergo alternative prenylation by GGTase I7 and could be targeted by 
competitive FTIs. Indeed, FTIs to target HRas-mutant cancers are currently being investigated in the 
clinic.9,10
Disruption of GTPase interactions with effector proteins has proven challenging as these 
conventional protein-protein interactions (PPIs) are mediated by relatively large, smooth surfaces 
that generally lack distinct binding pockets for small molecules. There has however been some 
recent success generating small molecule inhibitors of Ras, as Shokat and colleagues identified a 
small pocket beneath switch II which they were able to exploit to generate covalent inhibitors 
targeting the KRasG12C mutant.11 This has renewed the hope of using small molecules to inhibit 
small GTPases, although identification of similar binding pockets on other family members could 
prove very challenging. The advantage of covalent inhibitors is that compounds with lower affinity 
are still effective, meaning less well-defined binding pockets are required. Their application is 
limited however to reactive residues at therapeutically relevant sites, for example the rare mutants 
that result in an exposed cysteine residue.
Peptides offer an enticing opportunity for the inhibition of PPIs as they offer excellent selectivity and 
target binding affinity, even at relatively smooth protein surfaces, due to the large area that they 
occupy. In this way they retain many of the advantages of larger biologics, while their smaller 
molecular weight enables the possibility of cell entry. Initially peptides were limited to extracellular 
targets, however developments in the use of cell-penetrating peptides and research into the intrinsic 
properties that invoke cell uptake have opened up the peptide druggable space to encompass 
intracellular proteins such as the small GTPases. 
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Macrocyclization of peptides is one strategy that has been employed for targeting intracellular 
proteins (for a recent review see 12). Small cyclic peptides are typically resistant to proteases and 
have higher target affinities due to their reduced conformational freedom. Several cell-permeable 
cyclic peptides exist in nature, including the immunosuppressant cyclosporin A, which is also 
endowed with oral bioavailability, a property that has proven elusive to peptide chemists. 
Investigation into how these natural products achieve cell entry has been an active area of research 
(reviewed in 13) and has guided improvements in cellular permeability of synthetic peptides, for 
example by N-methylation of amide bonds.14,15 Some groups now also incorporate cell-permeable 
peptide (CPP) scaffolds as part of library design,16 thus eliminating effort spent on hits that cannot be 
converted to cell penetrant analogues and to eliminate the need to append bulky and often toxic 
CPPs. 
Macrocyclic binders are often derived from de novo peptide libraries, however an alternative 
strategy involves mimicking existing binding motifs from PPI interfaces. Analysis of available Protein 
Data Bank (PDB) structures revealed that more than 60% of known PPIs contain a helix in the 
interaction interface,17 therefore mimicry of this critical binding motif presents an opportunity for 
inhibitor design. However, when helical peptide sequences are isolated from larger proteins, they 
often lose secondary structure and so stabilization of α-helical peptides has emerged as an elegant 
chemical solution to generate rigid, high affinity peptides with improved drug-like properties. The 
most commonly used example of -helix stabilization is the all-hydrocarbon staple introduced by 
Verdine and colleagues.18 This approach utilises olefin-containing amino acids of appropriate lengths 
at either i, i + 4 or i, i +7 positions of a peptide, which are then covalently linked by a Grubbs ring 
closing metathesis, though many other strategies exist and have been reviewed recently.19,20 With 
careful staple positioning, the stabilized helical structures can have improved affinity due to a 
reduced entropic penalty upon binding, while in certain instances the staple itself can also interact 
favourably with the target protein.21 The incorporation of unnatural amino acids and increased 
secondary structure often improve the proteolytic stability of the peptides and can also facilitate cell 
permeability.22,23 Many peptides have been designed to disrupt GTPase effector or regulator 
interactions (Table 1) and these will be discussed in detail in this review. 
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Switch II residues 
92-108 of DiRas3 58
Trio (RhoGEF) TRIP Linear
Yeast two hybrid 
with aptamers 63
Tgat (RhoGEF) TRIPE32G Linear




























Arf Arf1 N-terminus mimic MTM-Arf1
2-17 Linear, CPP-
conjugated Arf1 residues 2-17 75
2 Ras family
The Ras proteins (HRas, KRas4A, KRas4B and NRas) are known to be the most commonly mutated 
oncoproteins in human cancer with activating mutations identified in approximately 20% of human 
tumours and far higher incidences observed in certain cancers e.g. KRas4B in pancreatic (98%) and 
colorectal (50%) cancers.24 Oncogenic Ras proteins are typically mutated at positions 12, 13 or 61: 
these favour the GTP-bound form, rendering Ras constitutively active.25 As a result of their 
prevalence in disease, Ras proteins have been the subjects of intense targeting for more than 35 
years but despite these efforts there are currently no therapeutics in the clinic that target Ras 
proteins directly. 
2.1 Identification of Ras peptide binders from naïve selections
2.1.1 KRpep-2d
A group at Takeda aimed to identify peptide inhibitors of oncogenic KRas signalling using random 
libraries in combination with phage display. They screened 1011 peptides of varying sizes against the 
commonly occurring KRasG12D mutant, with phage removed that bound wild-type KRas to enrich for 
mutant-specific binders.26 From this selection they identified a disulphide-linked cyclic peptide, 
KRpep-2 (Figure 2A), with a Kd for KRasG12D of 50 nM, which displayed impressive selectivity over 
wild-type KRas with 14-fold tighter binding. Addition of a reducing agent drastically decreased 
binding, demonstrating the importance of the cyclic structure, and a linear control peptide was 
unable to bind. 
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The KRpep-2 sequence served as the template for a maturation phage library with the aim of further 
improving affinity for KRasG12D. The most enriched sequence from this library was an identical 
peptide with two extra Arg residues at the N- and C-termini (KRpep-2d, Figure 2A) that displayed 5-
fold improved affinity for KRasG12D.27 This peptide decreased phospho-ERK levels downstream of Ras 
in a KRasG12D mutant cancer cell line (A427) following dosing at 30 μM but had no effect in a KRasG12C 
mutant background (A549). The proliferation of the A427 cells was impaired while A549 cells were 
unaffected, suggesting that this effect was due to KRas mutant-specific inhibition rather than 
peptide cytotoxicity. The mode of action of KRpep-2d is likely to be due to disruption of GEF-
mediated nucleotide exchange, as in vitro experiments showed that the peptides could inhibit 
exchange of GDP for GTP in the presence of the Ras-GEF SOS1, thus preventing activation of 
KRasG12D. The group went on to solve the crystal structure of KRpep-2d in complex with KRasG12DGDP 
(PDB ID: 5XCO). Interestingly, the peptide binding site is distinct from the SOS1 binding interface and 
instead KRpep-2d occupies a unique allosteric site on KRas that is adjacent to switch II and the α3 
helix (Figure 2B).27 The peptide appears to form interactions with switch II (Figure 2C), forcing switch 
II into a conformation that is unfavourable for binding the helical hairpin of SOS1, explaining the 
observed reduction in SOS1-mediated exchange.
There are, of course, always concerns that disulphide-linked peptides will not remain cyclized in the 
reducing environment of the cytoplasm and activity will consequently be lost. To circumvent this 
issue the group investigated several bridging moieties between the two Cys residues of KRpep-2d to 
produce covalently linked analogues that would be resistant to reduction.28 Of these, a mono-
methylene (-CH2-) bridge gave rise to the most potent analogue (IC50 of 18nM, a modest reduction 
compared to the IC50 of 1.6 nM exhibited by KRpep-2d), which also maintained selectivity for the 
KRasG12D mutant. This was the shortest linkage tested and was closest to the length of the native 
disulphide bond. Molecular dynamics simulations indicated that the positions of critical side chains 
Leu7, Ile9 and Asp12 (identified by Ala-scanning) were maintained with the slightly larger ring size, 
whereas a much larger bridging molecule, o-xylene, greatly affected the overall peptide structure, 
explaining its much weaker inhibition of KRasG12D. In vitro assays proved that the methylene-bridged 
peptide maintained inhibition upon the addition of reducing agent, however unexpectedly the 
peptide did not display superior performance in cell-based assays, with the stabilized peptide 
exhibiting similar inhibition to the disulphide-linked KRpep-2d. This suggests that the disulphide 
linkage in KRpep-2d was maintained inside the cell for long enough for the peptide to exert an effect 
on Ras signalling, challenging the assumption that a disulphide-linked peptide would be unsuitable 
for an intracellular target. It is also possible that the introduction of the methylene group reduced 
cell penetration.
Nevertheless, the high concentrations of these peptides needed for dosing in cell-based assays 
compared to their in vitro affinity suggest that cell entry is poor. Although the peptides only 
produced minimal effects in cell culture, they could be further developed using new delivery 
methods including nanoparticles and lipid formulations or by appending a CPP. This is the first 
example of a peptide that can selectively inhibit a single KRas mutant, providing significant 
advantages over previous approaches where the lack of specificity over wild-type KRas could lead 
to significant toxicity issues. This identification of a novel allosteric binding pocket on KRas also 
offers new options to drug this highly elusive cancer target. 
2.1.2 Cyclorasins
The Pei group set out to identify inhibitors of another commonly occurring KRas mutant, G12V, using 
a synthetic library of cyclic peptides incorporating a rapamycin analogue or ‘rapalog’, a minimal 
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motif to recruit FK502-binding protein 12 (FKBP),29 together with four to six variable amino acid 
positions for binding to KRasG12V.30 The recruitment of the 12 kDa FKBP protein is used to create a 
steric block which extends further than the small peptide and therefore could prevent effector 
binding if oriented correctly. 
Peptides selected from the screen that bound to both KRasG12V and FKBP all had the largest ring size 
tested, containing six variable amino acid positions. Interestingly, many of the peptides were able to 
inhibit the KRasG12V-Raf interaction in vitro in the absence of FKBP, indicating that the peptides are 
bound directly at the effector binding site. The most promising peptide identified, compound 12 
(Figure 3A), had a Kd of 0.83 µM for KRasG12V and was able to inhibit a panel of Ras-effector 
interactions, although no cellular activity was observed due to poor uptake of the peptide.
The apparent lack of cellular uptake for compound 12 was surprising as it contained an Arg-Arg-Nal-
Arg-Fpa (Nal = D--naphthylalanine, Fpa = L-4-fluorophenylalanine) sequence which closely 
resembled potent CPPs recently identified by the group.31 A second synthetic cyclic library to search 
for intrinsically cell penetrant KRasG12V inhibitors was constructed with the Arg-Arg-Nal-Arg-Fpa core 
sequence in addition to between one and five randomised positions.32 One of these hits, Cyclorasin 
9A, showed some cell permeability and had a relatively potent IC50 of 0.65 µM for the Ras-Raf 
interaction in vitro. This peptide was further optimised based on insights from an Ala scan. The 
substitution of a Gln for Arg in conjunction with other modifications resulted in a much more cell-
permeable peptide, Cyclorasin 9A5 (Figure 3B), which displayed diffuse cytosolic localization and 
around 4-fold higher affinity for KRasG12V. The peptide showed preference for the GTP-bound form of 
KRasG12V over GDP, indicating that it was binding at or near the switch regions and this was 
supported by NMR titration experiments. Cyclorasin 9A5 had an anti-proliferative effect on H1299 
(NRasQ61K mutant) lung cancer cells and showed a reduction in phosphorylation of targets 
downstream of Ras (MEK, ERK and Akt) at dosing concentrations above 3 µM. However, the peptide 
was not able to discriminate between Ras isoforms or between mutant and wild-type KRas, which 
could lead to future cytotoxicity issues.
2.1.3 Bicyclic Ras inhibitors
The same group also used a synthetic library of bicyclic peptides, 6-10 residues in size, to identify 
inhibitors of KRasG12V.33 They identified peptides with low micromolar affinity, of which one, 
Cyclorasin B3, showed preference for KRasGTP over the GDP-bound form and was competitive with 
Raf Ras-binding domain (RBD) binding. Monocyclic and linear forms of the peptide had reduced 
affinities, indicating the benefit of the rigidified structure. The addition of oleic acid to aid cell 
penetration resulted in a peptide with only modest antiproliferative activity in a lung cancer cell line.
They went on to design a second bicyclic peptide library based on a scaffold in which one of the rings 
encompassed a cyclic CPP previously identified by the group, cFΦR4, where Φ is L-2-napthylalanine,31 
and the second ring contained five positions which could include a variety of proteinogenic and 
unnatural amino acids to generate target binding affinity.16 This approach was used to again search 
for a direct KRasG12V inhibitor. L-propargylglycine (Pra) was included in the peptide sequence and was 
coupled through click chemistry to 4,6-dichloro-2-methyl-3-aminoethylindole (DCAI), a previously 
identified KRas small molecule inhibitor with Kd ~ 1 mM that is known to bind proximally to the 
effector binding region on KRas. This was included with the twin aims of generating peptides that 
bind close to the effector binding site and improving affinity.
The hit with the best in vitro binding affinity (5 µM) was selected for further optimisation and 
additional Ala residues were added to the ring to determine whether affinity could be improved with 
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ring expansion. It was found that addition of three Ala residues gave a 5-fold improvement in 
binding affinity. This larger template formed the basis of a maturation library in which the three Ala 
residues were replaced with a selection of 25 natural and unnatural amino acids. The second library 
did not produce a peptide with improved affinity, however it did show that D-Leu and Asp could be 
included to improve proteolytic stability and solubility. The optimised peptide 49 (Figure 3C) showed 
a dramatic reduction in binding when the DCAI molecule was removed (0.21 µM vs 17 µM) indicating 
that the binding site for the DCAI was conserved and indeed competition experiments with free DCAI 
proved this to be the case. Binding of peptide 49 was shown to be competitive with the Raf RBD but 
displayed little preference for the nucleotide state of KRasG12V, which is surprising given that the 
conformation of the Raf-binding region changes dramatically depending on whether KRas is bound 
to GDP or GTP. The binding of the peptide to wild-type KRas or mutants other than G12V was not 
reported, although general selectivity of the peptides for KRasG12V over unrelated control proteins 
was demonstrated. Inhibition of signalling downstream of Ras was investigated in two Ras mutant 
lung cancer cell lines and reduction of p-Akt and p-MEK levels were observed with 18 μM dosing of 
peptide 49, indicating that the peptide is cell-penetrant and able to reach its target, while a control 
peptide lacking the DCAI moiety had no effect.
2.2 Inhibition of the Ras-GEF interaction
2.2.1 Hydrogen bond surrogate SOS1 peptides 
The first peptides to inhibit Ras based on the Ras-GEF, SOS1, were generated by Patgiri et al. who 
noted that within the helical hairpin region of SOS1, the majority of contacts with KRas are made by 
one helix, αH (Figure 4A, PDB: 1NVW).34 Computational models combined with mutagenesis data 
revealed that Phe929-Asn944 (Figure 4B) were the residues most critical for binding. They designed 
a peptide based on this sequence and utilised a hydrogen bond surrogate (HBS) approach in which 
the hydrogen bond between the backbone carbonyl of the N-terminal residue and the amine of the 
N + 4 residue is replaced with a covalent bond to stabilize a helical conformation.35 They improved 
the solubility and helicity of the peptide by replacing non-essential hydrophobic residues with 
charged residues that have the potential to form stabilizing i, i + 4 salt bridges. The resulting peptide, 
HBS3 (Figure 4B), had an affinity of 28 µM for nucleotide free Ras and 158 µM for the GDP-bound 
state. A titration with 15N labelled Ras and excess peptide to indicate residues involved in peptide 
binding showed several that were also involved in SOS1 binding. Accordingly, the peptide was able 
to inhibit SOS1-mediated exchange of GDP for GTP in vitro, while a control peptide with key residues 
mutated to Ala had little effect. 
Microscopy showed fluorescent peptide present inside the cell, with punctate staining suggesting 
that it could be trapped in endosomes. Despite this, an effect on Ras signalling was observed with 75 
μM peptide dosing, as shown by a reduction in phospho-Erk levels, suggesting that at least some of 
the peptide was able to escape into the cytosol and reach its target.
2.2.2 Hydrocarbon stapled SOS1 peptides
Walensky and colleagues also generated peptides based on the helical portion of SOS1 that is 
involved in KRas binding.36 They used all-hydrocarbon stapled peptides encompassing the same 
sequence (SOS1 929-944) with four different i, i + 4 staple positions. Binding to wild-type KRas and a 
panel of KRas mutants (G12D/G12V/G12C/G12S/Q61H) was assessed by fluorescence polarisation 
and three out of four peptides bound all KRas forms with affinities between 60 and 100 nM. The 
fourth peptide contained a staple position replacing residues that contact KRas in the SOS1 
structure, therefore disrupting the normal binding interface, and this peptide showed no binding. 
Two N-terminal Arg residues were appended to the peptides to alter the overall charge from -1 to 
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+1, as this has previously been shown to improve cell permeability.22 The peptide with the best 
solubility profile was taken forward for further evaluation along with the non-binding control 
peptide, and these modified peptides were named SAH-SOS1A (Figure 4B) and SAH-SOS1B 
respectively. SAH-SOS1A was able to disrupt KRas/SOS1 interactions in vitro and this was supported 
by NMR titration data with 15N labelled wild-type KRas and unlabelled peptide, which showed 
perturbation of several KRas residues implicated in SOS1 binding. The SAH-SOS1A peptide was able 
to block intrinsic nucleotide exchange as demonstrated by relative fluorescence using mant-labelled 
GTP and GDP but it was not reported whether the peptides could also inhibit SOS1-mediated 
exchange, which would be a requirement for inhibition in a cellular context. The SAH-SOS1A peptide 
decreased viability of a variety of cancer cells carrying either wild-type or mutant KRas, while the 
control peptide SAH-SOS1B had no effect, demonstrating a sequence-specific effect on the cells 
tested.
2.3 Targeting a Ras effector: inhibitors of Raf dimerization
Difficulties in targeting Ras directly have led many groups to look for targets downstream of Ras 
instead, including several proteins in the Raf-MEK-ERK pathway. The Raf isoform BRaf is itself 
frequently mutated in cancer and these mutations occur independently of activating Ras mutations. 
Several small molecules targeting the ATP-binding site of BRaf are available in the clinic and can be 
effective in treating Raf mutant cancers but have proven ineffective in treating Ras mutant cancers, 
as paradoxical activation of the pathway can occur leading to aggressive tumour recurrence.37,38 This 
activation occurs in part due to increased BRaf and CRaf hetero- and homodimer formation,37,38 
therefore inhibition of these dimers offers an opportunity to inhibit oncogenic Raf signalling or 
increase the potency of existing drugs. 
Freeman et al. first demonstrated the potential of using peptides to disrupt the Raf dimer 
interface.39 By screening several peptides forming segments of the dimer interface they identified 
residues 503-521 as an effective block of Raf heterodimer formation when expressed in cells: their 
expression led to decreased phosphorylation of MEK (a substrate of Raf), demonstrating the 
possibility of targeting this interface for therapeutic intervention. 
Beneker et al. truncated this peptide at each end and identified 504-518 as a tighter binder than the 
original sequence (0.13 vs 3.8 μM for 503-521).40 The shortened peptide 504-518 fused to a Tat CPP 
showed a reduction in paradoxical MEK activation in cells treated with Vemurafenib, another ATP-
competitive BRaf inhibitor. They used available dimer structures to identify possible cyclization 
points to stabilize the bioactive loop conformation and found several residues in close proximity as 
possible candidates. They cyclized the shorter peptide (505-518) by lactamization between positions 
508 and 513 (Figure 5) and replaced Asn512 with Ala to produce a peptide with a Kd of 61 nM for 
BRaf, while the linear counterpart had no detectable binding. Unfortunately, no cellular activity of 
the cyclic peptide was reported.
Another shortened peptide was generated by Gunderwala et al. who identified a 10mer 
encompassing residues 508-517 of BRaf from PeptiDerive predictive software using the crystal 
structure of BRaf dimers (Figure 5).41 Their CPP-conjugated peptide, Tat-braftide, acted 
synergistically with dabrafenib, a Raf ATP-binding site inhibitor, to alleviate the paradoxical 
activation that is seen with the use of ATP-competitive inhibitors alone. Despite the nanomolar 
potency reported in vitro, very high concentrations of Tat-braftide (75 μM) were required to see an 
effect in cell culture. 
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The binding site of these peptides overlaps with the Raf heterodimer interface so the peptides 
should have the ability to inhibit formation of BRaf homodimers and BRaf/CRaf heterodimers, whose 
role in resistance to traditional Raf inhibitors has been established.37,38 These studies demonstrate 
the tractability of targeting this previously unexplored dimerization interface for the treatment of 
Ras mutant cancers.
2.4 Targeting Ras multimers   
For years there has been conflicting data as to whether Ras functions as a monomer or forms higher 
order structures but there is now mounting evidence that Ras needs to form dimers or clusters in a 
cell in order to signal (reviewed in 42). The α4 and α5 helices, which are distal from the switch 
regions, have been suggested to drive dimer formation as the vast majority of active Ras crystal 
structures dimerise via these helices.43 Inhibition of this interface using a monobody, a small 
synthetic protein based on a fibronectin type III domain, inhibited oncogenic Ras signalling in cell 
culture and slowed tumour growth and progression in vivo in a nude mouse model bearing KRas 
mutant tumours.43,44 
Designed ankyrin repeat proteins (DARPins) have been used to inhibit Ras multimer formation 
through an interaction involving the α3-α4 helices of KRas, which have also been implicated as a 
possible interface driving dimer formation.45,46 Bery et al. used phage display with DARPin libraries 
to identify inhibitors of KRas and an X ray structure of one of their hits revealed that the DARPin 
interacts with the α3-α4 helices of KRas.47 The DARPin was able to inhibit mutant KRas dimerization, 
as well as inhibiting KRas-Raf interactions, leading to a decrease in signalling.
These insights provide a novel opportunity to inhibit Ras signalling through disruption of dimer 
formation, for which peptides could be utilised in a similar manner to the Raf dimerization inhibitors 
explored earlier (Section 2.3). This approach could be limited however, as a dimer-targeting tool 
may not be able to discriminate between wild-type and mutant Ras proteins.
2.5 RalA/B 
The Ral-GEF/Ral (Ras like) signalling pathway is activated downstream of active Ras and has been 
implicated as critical for the survival of several Ras mutant cancers.48,49 The two Ral proteins, RalA 
and RalB, are 82% identical and share the same panel of effectors. Despite the high degree of 
similarity they have divergent roles in tumorigenesis: RalA is required for anchorage-independent 
growth, while RalB is involved in invasion and metastasis.50,51 
We used our structure of the RalB/RLIP76 Ral-binding domain (RBD) complex to guide design of 
peptides to inhibit Ral-effector interactions (Figure 6A).52 The structure revealed that RLIP76 
interacts with RalB through a coiled-coil domain where more than 80% of the contacts with Ral are 
made through the C-terminal helix of the RLIP76 coiled-coil.53 This helix was used as a template to 
generate a series of all-hydrocarbon stapled peptides targeting Ral proteins. Stapling successfully 
produced peptides with greater helicity and improved target binding compared to the unstapled 
parent sequence. The tightest-binding peptide (Figure 6B) was selective for active Ral and was 
shown to be competitive with two Ral effectors, RLIP76 and Sec5. The stapled peptide could 
penetrate HEK293T cells and inhibited autophagy, a RalB-dependent process, in a GFP-LC3 assay. 
Work is currently underway in our lab to produce second generation peptides with higher affinity 
and improved cellular activity.
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In contrast to the tumorigenic Ras proteins, the closely related DiRas (Distinct subgroup of the Ras 
superfamily) proteins have been identified as tumour suppressors in breast and ovarian cancers as 
they inhibit growth and metastasis.54–56 DiRas3, the best-studied member, is downregulated in 60% 
of breast and ovarian cancers by transcriptional regulation and through silencing by methylation.57 
Another tumour-suppressor role for DiRas3 has recently been identified, through inhibition of Ras 
multimerization leading to decreased oncogenic Ras signalling.58 It was found that DiRas3 interacts 
with the α5 helix of Ras, which has been implicated as part of a potential Ras dimer interface.43 This 
finding suggests that peptides mimicking DiRas3 could be used to inhibit Ras multimers.
In contrast to its role as a tumour suppressor in breast and ovarian cancers, DiRas3 has been shown 
to interact with Beclin1 in the formation of the autophagosome initiation complex.59,60 Although 
autophagy can be a suppressor of tumorigenesis, the process has more commonly been shown to 
facilitate survival of dormant tumour cells in a nutrient-deprived environment and promote tumour 
survival and aggressiveness.61 Therefore, inhibitors of autophagy are highly desirable and could be 
used to increase the effectiveness of existing cancer therapeutics. 
As the site of interaction between DiRas3 and Beclin1 was previously unknown, Sutton et al. used a 
peptide array spanning the sequences of DiRas3 and Beclin1 to define the interacting residues. They 
identified the N-terminal region and switch II of DiRas3 as necessary for the interaction with Beclin1 
and went on to generate a peptide based on switch II of DiRas3 (residues 92-108, Figure 7) fused to a 
Tat CPP (Tat-D3S2). While many small GTPases have highly conserved switch regions, DiRas3 is 
distinct from other subfamily members in this region and shares only 35% sequence identity with 
DiRas1 and DiRas2 (Figure 7B) suggesting the potential for peptide specificity in this case. 
A Kd value of 1.9 nM between the peptide and Beclin1 was measured by surface plasmon resonance 
(SPR), although significant binding of the Tat sequence alone and a scrambled peptide control was 
also observed.  Cell entry was confirmed by flow cytometry, and viability of two ovarian cancer cell 
lines, SKOV3 and A2780, under amino acid starvation conditions was measured using a CellTiter-Glo 
assay after incubation with 50 μM Tat-D3S2, a scrambled control peptide or Tat alone. Only Tat-
D3S2 affected the viability of SKOV3 cells, however for A2780 cells reduced viability was observed 
for Tat-D3S2 and the scrambled control, indicating off-target effects and toxicity of the sequence. A 
reduction in autophagy in the SKOV3 cells after Tat-D3S2 treatment was confirmed by a western blot 
showing reduced LC3-II levels and through quantification of autophagosomes by transmission 
electron microscopy. 
3 Rho family
Several Rho family members play an established role in human cancer. In particular RhoA, Rac1 and 
Cdc42 have been implicated in the process of metastasis as a consequence of their role in regulation 
of the actin cytoskeleton.2 For Rho family members their deregulation most frequently occurs 
through overexpression of the GTPases and their GEFs or through loss of the negative regulatory 
GAP proteins, although rarer instances of activating mutations have also been observed.2,62 
3.1 RhoA
Schmidt et al. sought to identify peptides targeting a Rho-GEF, Trio, aimed at targeting the 
TrioGEFD2 domain that is responsible for activation of RhoA.63 The TrioGEFD2 domain was used as 
bait in a yeast two hybrid screen in which a library of 2 x 106 aptamers, short peptides fused to a 
thioredoxin scaffold, were screened. This approach allows in cellular screening, which is a more 
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rigorous test for target specificity, while confining the peptide within a folded protein protects it 
from proteolytic degradation. Three aptamers taken forward for further testing were found to bind 
Trio selectively when tested against a panel of related and unrelated proteins, but only TRIAP (Trio 
Inhibitory Aptamer), containing a 42 amino acid peptide, was able to inhibit the Rho-GEF function in 
vitro in a GDP release assay. The unscaffolded, linear peptide derived from TRIAP, termed TRIP 
(Trio Inhibitory Peptide), had very similar activity to the aptamer. However, while reducing the 
length of the peptide in the aptamer to residues 9-36 retained complete activity, truncations in the 
free peptide form were not tolerated and activity was lost. They went on to test the peptide in cell 
culture by expressing GFP-tagged TRIP, which was shown to interact with Trio, causing a reduction 
in cellular levels of active RhoA.
The group later used this peptide as a template to design peptides targeting Tgat, a Rho-GEF with 
reported oncogenic potential.64,65 Tgat is an alternatively spliced form of Trio, consisting of the Trio 
DH2 domain and a unique C-terminal extension. The original peptide, TRIP, displayed only very 
weak affinity for Tgat, as the peptide bound both the DH2 and PH2 domains of Trio. To search for 
peptides with tighter binding to Tgat, which lacks the PH2 domain, the Trio DH2 domain alone was 
used as bait in an optimization yeast two hybrid assay, in which TRIP aptamers were subjected to 
random mutagenesis. Tgat itself could not be used as bait as it is toxic when expressed in yeast. They 
found that a single E32G mutant improved the affinity of the peptide for Tgat from 90 to 7 μM and 
improved the Tgat GEF inhibition 15-fold. The mutated peptide had equivalent efficacy against Trio 
and Tgat but was selective over other Rho-GEFs and Rho family members tested. The peptide 
reduced RhoA activation levels in Tgat-expressing NIH3T3 cells and was able to inhibit Tgat-mediated 
transformation of the cells when co-expressed as a GFP fusion. Nude mice injected with NIH3T3 cells 
co-expressing Tgat and GFP-TRIPαE32G peptide had a dramatically reduced tumour onset and volume 
compared to those expressing Tgat in the absence of the peptide.
These studies provide strong validation of Rho-GEFs as therapeutic targets and demonstrate the 
benefit of inhibiting the RhoA/GEF interaction, although converting these large, linear peptides to 
proteolytically stable and cell-penetrant therapeutic candidates could prove challenging.
3.2 Cdc42
Cdc42 is another small GTPase that is upregulated in several cancer types.2 Work carried out in our 
lab aimed to develop a peptide inhibitor of Cdc42/effector interactions using naïve libraries of short 
linear (10/12mer), long linear (16/20/25mer) and cyclic sequences (14-18mer) with Cys residues at N 
+ 4 and C - 4 positions. CIS display66 was used to screen the libraries of peptides against active Cdc42 
and competitive binders were identified by elution with the G protein binding domain of ACK, an 
effector for Cdc42.67
This approach identified several enriched sequences of which one, a 16mer termed C1 identified 
from the cyclic library, displayed a Kd of 350 nM for Cdc42 and was competitive with the Cdc42 
effector, ACK. The binding was dependent on the cyclic structure of the peptide and addition of 
reducing agent or mutation of the Cys residues to Ser, disabling disulphide bond formation, ablated 
binding to Cdc42.
The cyclic C1 peptide was matured in a second CIS display selection in which the positions with 
lowest amino acid consensus were allowed to alter. Several sequences were identified with 
significantly higher affinity for Cdc42, giving 5 to 20-fold improvement compared to the parent (C1) 
sequence. An NMR titration with 15N-labelled Cdc42 and the matured peptide P7 demonstrated that 
the peptide binding site overlaps with known binding sites of multiple Cdc42 effectors. 
Page 12 of 35































































Upon addition of a nona-arginine cell-penetrating motif, P7 was able to enter cells and was used for 
phenotypic studies. The peptide inhibited proliferation and migration of a lung cancer cell line and 
was shown to interact directly with Cdc42 in cells by cellular thermal shift assays (CETSAs), unusually 
resulting in a destabilization of Cdc42 in the presence of P7.
3.3 Rac1
A group at Takeda used random library screening with T7 phage to search for inhibitors of the 
interaction between Rac1 and its GEF, DOCK2.68 In the selection, peptides that bound to DOCK2 
were eluted with Rac1 to select for competitive binding. A disulphide-containing cyclic peptide, DC-
pep4, with a low nanomolar IC50 value was shown to be selective for DOCK2 over the highly similar 
DOCK1 protein and was able to inhibit DOCK2-mediated exchange of GDP for GTP on Rac1. 
Interestingly, the peptide still exhibited tight binding, albeit with 10-fold lower affinity, in reducing 
conditions (Kd of 1.8 nM vs 0.17 nM in non-reducing conditions) in contrast with the previous 
examples of the cyclic KRas-binding peptide KRpep-2d and our Cdc42-binding peptides where 
maintenance of the disulphide was critical for the binding activity of the peptide.26,67
The peptide was further optimised by truncation of the three N-terminal residues and by addition of 
o-xylene to covalently link the cysteine residues. Several other linkers were tested but resulted in a 
loss of affinity as the ring size increased. DC-pep4 already contained three Arg residues at the C-
terminus and an additional five Arg residues were added across the N- and C-termini to promote cell 
penetration.
Cytosolic entry of the peptides was investigated by a novel method involving the conjugation of 
luciferin via a disulphide linkage to the peptide. Upon entry to the reducing environment of the 
cytosol, the luciferase substrate is released and produces a luminescent signal in cells transfected 
with luciferase. The peptide containing eight terminal arginines was shown to effectively penetrate 
the cytosol and induced inhibition of migration in a human B lymphocyte cell line (MINO) with an 
IC50 of approximately 120 nM. The group set out to improve cytosolic entry further by assessing the 
uptake of 13 known CPPs in addition to novel CPPs based on a viral protein from influenza A using 
their luciferin assay.69 They found that their novel CPP, termed PF5, and an octa-Arg motif both 
resulted in peptides with dramatically improved cellular uptake and a concordant improvement in 
inhibition of cell migration.
4 Rab family
The Rab proteins are deregulated in a broad range of human diseases including cancer, diabetes, 
neurodegenerative diseases and infectious diseases.5,70 This deregulation occurs due to 
overexpression of the GTPases or through upregulation via altered expression of their regulatory 
proteins.
4.1 Rab8a
Spiegel et al. set out to develop inhibitors of Rab-effector interactions and searched for Rab 
effectors that interact via α-helical motifs and bury an extensive surface area on binding, to act as 
templates for stapled peptide design. Multiple Rab effectors: R6IP, LidA, REP1 and Rabin8, were 
found to bind Rab proteins via an α-helix and a series of peptides based on these interacting helices 
was generated.71 Hydrocarbon stapling was effective at improving binding affinity, with increases of 
up to 200-fold compared to the linear precursors. Binding was observed for a range of Rab family 
members, and most peptides tested bound the nucleotide-free forms more tightly than the GDP or 
GTP-bound proteins. It was hypothesised that this is due to the possibility of an induced fit upon 
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binding as a result of increased flexibility in the nucleotide-free structure. Promisingly, the stapled 
peptide StRIP3 (based on R6IP, Figure 8A and B) bound Rab8aGTP with an affinity of ~20 µM and 
was able to compete for the Rab8a/OCRL1 effector interaction. This peptide was optimised further 
to improve affinity, cell uptake and proteolytic stability.72 The incorporation of a second staple 
slightly improved the affinity for Rab8a and the resulting peptide, StRIP14 (Figure 8B), displayed a Kd 
of 7.8 μM and bound Rab8a more than 10-fold tighter than related Rab family members. This 
double-stapled peptide had dramatically improved proteolytic stability, from the StRIP3 t1/2 of 0.30 
min to more than 95% of the peptide remaining after 48 hours in a proteinase K degradation assay. 
Cell permeability was achieved by the replacement of negatively charged residues (Asp, Glu) with 
their neutral analogues (Asn, Gln) after an arginine scan showed that substitutions with Arg residues 
were not well tolerated. The resultant peptide was able to enter cells with a similar efficiency to the 
CPP Tat49-57 sequence and displayed endomembrane localization that overlapped with that of Rab8a. 
4.2 Rab25 
Peptides for Rab25 have also been generated based on the Rab11 family of interacting proteins, the 
FIPs, which bind Rab11/25 proteins using an α-helix followed by a turn and a short 310 helix (Figure 
8C).73 Stapled peptides based on the Rab binding domains of FIP1-4 were generated, leading to the 
identification of stapled peptides which bound with sub-micromolar affinity and displayed 
preference for Rab25 over Rab11a. Cellular penetration was improved by the replacement of anionic 
residues with neutral polar or cationic residues and with the addition of extra charge at the peptide 
terminus. The optimised peptide RFP14 (Figure 8D) was able to effectively enter HEY cells (an 
ovarian cancer cell line) and reversed the global expression profile associated with Rab25 
overexpression. 
5 Arf family
The small GTPase Arf1 has been implicated in allergic responses and inflammation: Nishida et al. 
demonstrated that Arf1 activation results in mast cell degranulation and set out to develop 
inhibitors of this activation as a potential treatment for inflammation.74 
The group generated peptides based on the N-terminal region of Arf1 fused to a CPP called MTM.75 
Having previously identified that MTM-Arf1 (residues 2-17) inhibited mass cell degranulation,74 they 
aimed to find the minimal binding sequence required for such an effect. Truncation from the C-
terminus showed that Lys15 and Lys16 were essential for the activity of the peptide, while Glu17 
could be lost with no significant effect on activity. At the N-terminus, removal of amino acids up to 
Lys10 did not dramatically effect activity but Lys10 itself was shown to be essential. The shortened 
peptide MTM-Arf1(8-16) inhibited cytokine production and caused a decreased allergic response in a 
mouse model of anaphylaxis. Unfortunately, no studies were carried out to elucidate the mechanism 
of action of the peptide, although it was proposed that the peptide can block Arf1 localization at the 
membrane, which is essential for its function.76 Arf1 requires myristoylation at its N-terminus for 
membrane localization and the peptide lacks the N-terminal Gly residue that is normally modified 
and so cannot be exerting its effect through inhibition of the myristoylation event. Instead, the 
authors hypothesized that the three essential lysine residues in the peptide play a critical role in its 
mode of action by inhibiting the interaction of Arf1 with membrane phospholipids, particularly PIP2. 
The N-terminal region of Arf1 explored in this study forms a helix, so a peptide based on this region 
could benefit from helix stabilization chemistries to protect the peptide from proteolytic 
degradation and potentially improve cell penetration without the use of a CPP. 
Page 14 of 35
































































The examples discussed in this review clearly show that peptides with high affinity and selectivity 
can be generated for a wide range of targets. The in vivo activity of these peptides, however, is often 
limited by poor and unpredictable cell penetration properties. Examination of cell-permeable 
macrocycles from nature has provided valuable insights into peptide design, including N-methylation 
of backbone residues which has helped to improve permeability of synthetic peptides.14,15 The 
advent of peptide stapling and subsequent studies into the cell-penetrating properties of such 
peptides have provided a set of design principles for targeting intracellular targets mediated via α-
helices, improving the chances of producing successful compounds.22,23,77 While there is still no 
universal strategy for generating cell-permeable peptides, our understanding of the properties 
determining cell penetration will only continue to increase and with that will come a dramatic rise in 
the effectiveness of peptides for intracellular targets. It is unlikely that a single approach can be 
applied to all of the small GTPases, however with so many avenues being explored to disrupt their 
function including the use of peptides, covalent inhibitors, DARPins and monobodies, it is only a 
matter of time before effective therapeutics reach the clinic and serve as inspiration for targeting 
other members of this highly important family of proteins.
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CETSA Cellular thermal shift assay
CPP Cell-penetrating peptide
DARPin Designed ankyrin repeat protein
FTI Farnesyltransferase inhibitor
GAP GTPase activating protein
GDI Guanine nucleotide dissociation inhibitor
GDP Guanosine diphosphate
GEF Guanine nucleotide exchange factor
GFP Green fluorescent protein
GGTase Geranylgeranyltransferase
GTP Guanosine triphosphate
PDB Protein Data Bank
PPI Protein-protein interaction
RBD Ras/Ral-binding domain
SPR Surface plasmon resonance
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Figure 1. The Ras superfamily of small GTPases. A. Selected members of the human Ras superfamily. 
Proteins that have been targeted by peptides and are covered in this review are highlighted in red. 
B. The GTPase cycle. GTPases are inactive when bound to GDP. Ras, Rho and Rab proteins have 
associated GDIs and GDI-like partners that can extract them from the membrane in this form, 
sequestering them in the cytosol. Binding of a GEF causes exchange of GDP for GTP by promoting the 
loss of GDP followed by GTP binding, which occurs as a result of far higher intracellular 
concentrations of GTP. In the GTP-bound form the small GTPases are activated and are competent in 
effector binding. They are then deactivated by binding to GAPs, which stimulate hydrolysis of GTP to 
GDP. The vast majority of small GTPases are lipid modified and are membrane bound. 
Figure 2. Cyclic peptide KRpep-2d binding to KRas. A. Sequences of KRpep-2 and KRpep-2d. Cys 
residues that cyclize the peptide are highlighted in red. B. Crystal structure of KRpep-2d bound to 
KRasG12DGDP (PDB ID: 5XCO). KRas is shown in blue, with switch I (yellow) and switch II (green) 
highlighted. GDP nucleotide is shown as sticks. The peptide (orange) binds at a site proximal to 
switch II and the α3 helix. C. Zoom of the structure with contacts formed between KRpep-2d and 
KRas shown as dashed lines, including a hydrogen bond between the backbone NH of KRpep-2d Tyr8 
and the backbone carbonyl of Gln61 on KRas (indicated by *). 
Figure 3. Macrocyclic Ras inhibitors. A. Compound 12 identified from a screen of cyclic peptides 
incorporating a FKBP binding motif (red). Amino acid positions varied in the screen are labelled 1-6. 
B. Structure of Cyclorasin 9A5, a cyclic peptide identified from a library of peptides containing a CPP 
sequence identified previously (blue) and up to 5 variable amino acid positions (labelled 1-5). C. 
Structure of an optimised hit from a bicyclic library screen, peptide 49. DCAI = 4,6- dichloro-2-
methyl-3-aminoethylindole, a KRas inhibitor (green).
Figure 4. Helical peptides targeting the Ras-SOS1 interaction. A. Crystal structure of nucleotide 
free HRas (blue; switch I, yellow; switch II, green) in complex with SOS1 (grey, PDB ID: 1NVW). 
Residues 929-944 of SOS1 are coloured in orange. B. Peptides generated based on SOS1. X = (S)-
pentenylalanine, Z = 4-pentenoic acid. Substitutions from the parent sequence are shown in red.
Figure 5. Inhibition of Raf dimerization. A. Crystal structure of active Raf dimers (PDB: 4E26). One 
monomer is displayed in blue and the other in grey with residues 504-518 coloured in orange. Zoom 
shows the position of residues 508 and 513 as sticks that were used for lactamization by Beneker et 
al.38 B. Peptides designed to inhibit BRaf dimer formation. Residues altered from the original Raf 
sequence are shown in red. The cyclic peptide has undergone lactamization at Lys4 (BRaf numbering 
508) and Glu9 (BRaf 513).
Figure 6. Inhibition of Ral GTPases. A. NMR structure of RalBGMPPNP (blue; switch I,  yellow; switch 
II, green) in complex with the RLIP76 RBD (grey, residues 423-446 in orange, PDB ID:2KWI). 
GMPPNP is shown as sticks and the Mg2+ cation is displayed as a yellow sphere. B. The sequence of 
the tightest binding peptide identified based on the RLIP76 RBD is shown. X = (S)-pentenylalanine.
Figure 7. Inhibition of DiRas3. A. Crystal structure of DiRas2 (blue; Switch I, yellow; PDB ID:2ERX) 
with switch II residues that form the basis for the DiRas3-derived peptide shown in orange. GDP is 
shown as sticks and the Mg2+ cation is represented by a yellow sphere. B. A sequence alignment of 
switch II from the three DiRas isoforms shows large disparity between DiRas3 compared with DiRas1 
and 2. Identical and similar residues are coloured orange; divergent residues are coloured black.
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Figure 8. Helical effectors for Rab proteins as the basis for peptide inhibitors. A. Crystal structure of 
Rab6GTP (blue; switch I, yellow; switch II, green) in complex with R6IP (grey; residues 900-916, 
orange; PDB ID: 3CWZ). The nucleotide is shown as sticks and the Mg2+ cation is represented by a 
yellow sphere. B. Peptide sequences derived from residues 900-916 of R6IP. C. Crystal structure of 
Rab25GMPPNP (blue) in a symmetrical dimer complex with FIP2 (grey; residues 471-500, orange; 
PDB ID: 3TSO). The region of FIP2 highlighted in orange is equivalent to residues 1245-1274 in FIP1. 
D. Sequence of peptide RFP14 derived from FIP1 (1245-1274). Residues that have been modified 
from the original sequence are highlighted in red. X = (S)-pentenylalanine, NL = norleucine,  = 
beta-alanine.
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